Journal: Oncotarget

Article Title: Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker

doi: 10.18632/oncotarget.14410

Figure Lengend Snippet: Distribution of RTKs, MED12, and TGF-βRII stratified by IHC total score in SCLC tumors as shown in Figure 2 (n=125)

Article Snippet: Rabbit anti-human polyclonal MED12 antibody (NB100-2357, Novus Biologicals, Littleton, CO, USA), rabbit anti-human polyclonal TGF-βRII antibody (NB100-91994, Novus Biologicals), rabbit anti-human polyclonal c-kit antibody (A4502, Dako, Glostrup, Denmark), rabbit anti-human polyclonal HER2 antibody (A0485, Dako), rabbit anti-human monoclonal c-Met antibody (EP1454Y, Abcam, Cambridge, UK), rabbit anti-human monoclonal VEGFRII antibody (#2479, CST, Danvers, MA, USA), mouse anti-human monoclonal EGFR antibody (31G7, Nichirei Biosciences, Tokyo, Japan), and mouse anti-human monoclonal ALK antibody (5A4, ab17127, Abcam) were used as first antibodies.

Techniques:

Journal: Oncotarget

Article Title: Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker

doi: 10.18632/oncotarget.14410

Figure Lengend Snippet: Univariate analysis of the association between molecular expression and OS (n=107)

Article Snippet: Rabbit anti-human polyclonal MED12 antibody (NB100-2357, Novus Biologicals, Littleton, CO, USA), rabbit anti-human polyclonal TGF-βRII antibody (NB100-91994, Novus Biologicals), rabbit anti-human polyclonal c-kit antibody (A4502, Dako, Glostrup, Denmark), rabbit anti-human polyclonal HER2 antibody (A0485, Dako), rabbit anti-human monoclonal c-Met antibody (EP1454Y, Abcam, Cambridge, UK), rabbit anti-human monoclonal VEGFRII antibody (#2479, CST, Danvers, MA, USA), mouse anti-human monoclonal EGFR antibody (31G7, Nichirei Biosciences, Tokyo, Japan), and mouse anti-human monoclonal ALK antibody (5A4, ab17127, Abcam) were used as first antibodies.

Techniques: Expressing

Journal: Journal of Clinical Microbiology

Article Title: Development and Characterization of a Highly Specific and Sensitive SYBR Green Reverse Transcriptase PCR Assay for Detection of the 2009 Pandemic H1N1 Influenza Virus on the Basis of Sequence Signatures ▿ †

doi: 10.1128/JCM.01142-10

Figure Lengend Snippet: Human samples detected with a 2009 H1N1 NA signatures SYBR green-specific assay. Performance and accuracy of the 2009 H1N1 NA signatures SYBR green assay were assessed with 125 human clinical samples (nasopharyngeal swabs or tracheal aspirates) obtained from individuals presenting with influenza-like symptoms during the 2009 H1N1 influenza outbreak in Chile (May to August 2009). Results are plotted as the CT values obtained with the CDC 2009 H1 assay versus the CT values obtained with the 2009 H1N1 NA signatures SYBR green assay. The limits of detection for each assay were 37 and 35 cycles, respectively, and these are depicted as dotted lines on each axis. Regression curves made with 10-fold serial dilution standards were between 0.984 and 0.995 in two independent runs for each assay. Dots indicate the mean CT signal obtained for triplicate reactions per sample for each assay performed, in a final volume of 10 μl, in a 384-well plate using a Roche LightCycler 480 real-time PCR system. Samples that were over the limit of detection were considered negative for each specific assay.

Article Snippet: The SYBR green assays using the 2009 H1N1 NA signature primers were performed in two formats: a 96-well plate assay was done using a CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA) in a final volume of 25 μl, and a 384-well plate assay was performed in a LightCycler 480 real-time PCR system (Roche, Indianapolis, IN) in a 10-μl final reaction volume.

Techniques: SYBR Green Assay, Serial Dilution, Real-time Polymerase Chain Reaction